In a phase II study, AD patients treated with telazorlimab demonstrated suppression of Th2, Th1, and Th17/Th22 cytokines in the treatment arm with reductions in OX40+ T cells and OX40L+ dendritic cells. The gene discussed is TNFRSF4; the disease is Alzheimer disease.